Your browser doesn't support javascript.
loading
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Aguado de la Rosa, Carlos; Cruz Castellanos, Patricia; Lázaro-Quintela, Martín; Dómine, Manuel; Vázquez Estévez, Sergio; López-Vivanco, Guillermo; Fírvida Pérez, José Luis; Alonso Romero, José Luis; Ferrera Delgado, Lioba; García Girón, Carlos; Diz Taín, Pilar; Álvarez Álvarez, Rosa; Mut Sanchís, Pilar; Fernández Cantón, Inmaculada; Manrique Abós, Isabel; Martínez Aguillo, Maite; Gómez-Aldaraví Gutiérrez, Lorenzo; Ortega Granados, Ana Laura; Álvarez Cabellos, Ruth; García Sebastián, Arancha; García Sifuentes, Luis Fernando; Reguart, Noemí.
Affiliation
  • Aguado de la Rosa C; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain.
  • Cruz Castellanos P; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
  • Lázaro-Quintela M; Department of Medical Oncology, Hospital Alvaro Cunqueiro, Vigo, Spain.
  • Dómine M; Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Vázquez Estévez S; Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • López-Vivanco G; Department of Medical Oncology, Hospital Universitario de Cruces, Baracaldo, Spain.
  • Fírvida Pérez JL; Department of Medical Oncology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain.
  • Alonso Romero JL; Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, IMIB-Arrixaca, Spain.
  • Ferrera Delgado L; Department of Medical Oncology, Hospital Universitario de La Candelaria, Santa Cruz de Tenerife, Spain.
  • García Girón C; Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain.
  • Diz Taín P; Department of Medical Oncology, Hospital Universitario de León, León, Spain.
  • Álvarez Álvarez R; Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Mut Sanchís P; Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain.
  • Fernández Cantón I; Department of Medical Oncology, Hospital Universitario de Jerez, Cádiz, Spain.
  • Manrique Abós I; Department of Medical Oncology, Hospital San Pedro de Logroño, La Rioja, Spain.
  • Martínez Aguillo M; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain.
  • Gómez-Aldaraví Gutiérrez L; Department of Medical Oncology, Hospitalario Universitario de Albacete, Albacete, Spain.
  • Ortega Granados AL; Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Spain.
  • Álvarez Cabellos R; Department of Medical Oncology, Hospital Universitario de Toledo, Toledo, Spain.
  • García Sebastián A; TFS Health Science at Pfizer, Madrid, Spain.
  • García Sifuentes LF; Medical Department, Pfizer Oncology, Madrid, Spain.
  • Reguart N; Department of Medical Oncology, Thoracic Oncology Unit, Hospital Clinic Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain. Electronic address: NREGUART@clinic.cat.
Lung Cancer ; 173: 83-93, 2022 11.
Article in En | MEDLINE | ID: mdl-36162227

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: Spain

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: Spain